Retatrutide (GLP-3)
$49.99
Retatrutide (LY3437943) is an investigational peptide studied for its activity at multiple metabolic hormone receptors, including GLP-1, GIP, and glucagon receptors. It has been evaluated in clinical research related to metabolic and endocrine signaling pathways and is being explored for its potential role in weight and energy regulation mechanisms.
Usage Disclaimer: Research Use Only. This product is intended strictly for laboratory research and in-vitro studies. It is not for human or animal consumption, medical use, or diagnostic purposes. Any unauthorized use of this product is strictly prohibited.
FDA Compliance: FDA Notice. The statements made regarding these products have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Research Studies
Phase III TRIUMPH-4 Trial - Eli Lilly (Dec 2025)
Human | 9-12mg weekly | 68 weeks | 28.7% weight loss (71.2 lbs)
First successful Phase III trial in 445 adults with obesity and knee osteoarthritis. 12mg dose achieved 28.7% weight loss (71.2 lbs from 248.5 lb baseline) with 75.8% pain reduction. Discontinuation rates 12-18% due to GI effects; new dysesthesia signal in 8.8-20.9% of participants.
MASLD Substudy - Nature Medicine (2024)
Human | 8-12mg weekly | 24 weeks | 82% liver fat reduction
Metabolic dysfunction-associated steatotic liver disease study showing dramatic liver fat reductions with normalization in over 90% of participants at highest doses.
TRIUMPH-Outcomes Cardiovascular Study (2024-2029)
Human | 8mg weekly | 248 weeks | 10,000 participants with ASCVD
Major cardiovascular outcomes trial assessing effects on MACE and kidney outcomes in participants with obesity and established cardiovascular or kidney disease.
Pair your peptide order with bacteriostatic water for proper reconstitution and storage. Adding it now ensures you have everything you need when your order arrives.
Avoid delays and complete your setup in one shipment.
